The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s therapeutic BCG vaccines market report forecasts the therapeutic BCG vaccines market size to grow to $65.62 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Therapeutic BCG Vaccines Market Report 2023 – https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Therapeutic BCG Vaccines Market Size Forecast
The global therapeutic BCG vaccines market is expected to grow from $50.73 billion in 2022 to $53.18 billion in 2023 at a compound annual growth rate (CAGR) of 4.82%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global therapeutic BCG vaccines market size is expected to grow to $65.62 billion in 2027 at a CAGR of 5.40%.

Asia-Pacific held the largest therapeutic BCG vaccines market share.

Key Therapeutic BCG Vaccines Market Driver ­– Rise In Number Of Tuberculosis Cases Worldwide
According to a report published in October 2022 by the World Health Organisation, a United Nations specialised agency responsible for international public health, 10.6 million people were predicted to have contracted tuberculosis (TB) in 2021, a 4.5% increase from 2020, and 1.6 million died from TB (including 187,000 HIV-positive individuals). As a result, the growing number of tuberculosis (TB) cases worldwide is propelling the therapeutic BCG vaccination market forward.

Request for A Sample Of The Global Therapeutic BCG Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9178&type=smp

Key Therapeutic BCG Vaccines Market Trend – Strategic Partnerships
To maintain their market position, major businesses in the therapeutic BCG vaccination market are focusing on cooperating with other key competitors. For example, in July 2021, Zendal, a Spanish pharmaceutical business, teamed with a non-profit organisation in the United States to move the tuberculosis vaccine candidate MTBVAC into efficacy studies. MTBVAC is the only live, attenuated Mycobacterium tuberculosis vaccine currently in development. It is now being developed as a more potent and perhaps long-lasting vaccine than BCG for newborns to prevent tuberculosis in adults and adolescents, for whom there is now no effective vaccination, as well as a more potent and potentially long-lasting vaccine than BCG for infants. This statement correlates with the rapid development of various COVID-19 vaccines.

Therapeutic BCG Vaccines Market Segment
1) By Type: Therapy BCG, Immune BCG
2) By Demographics: Pediatrics, Adults
3) By End Use: Hospitals, Clinics, Other End Users

Therapeutic BCG Vaccines Market Major Players and Strategies
Major players in the therapeutic BCG vaccines market are Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, BB-NCIPD Ltd., Biomed Lublin S.A., PowderJect Pharmaceuticals, Microgen, Taj Pharma Ltd. and BioFarma.

Sanofi S.A., a French multinational pharmaceutical and healthcare firm, acquired Amunix for an undisclosed sum in February 2022. This acquisition gives Amunix Pro-XTEN, XPAT, and XPAC technology access to offer next-generation conditionally activated biologics. Sanofi’s attempts to accelerate and expand its contributions to cutting-edge medicines for oncology patients are aided by the technology platform, which currently has roughly 20 compounds in development. It is an ideal complement to Sanofi’s existing R&D platforms. Amunix is an immuno-oncology firm established in the United States that aims to find, design, and commercialise innovative biologics, proteins, and peptide therapies.

The Therapeutic BCG Vaccines Global Market Report 2023 covers regional data on therapeutic BCG vaccines market size, therapeutic BCG vaccines market trends and drivers, opportunities, strategies, and therapeutic BCG vaccines market competitor analysis. The countries covered in the therapeutic BCG vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Therapeutic BCG vaccination is a vaccine that provides protection against tuberculosis, also known as tuberculosis. The therapeutic BCG vaccine (Bacillus Calmette-Guérin vaccine) is not included in the usual NHS vaccination schedule. A single dose of the BCG vaccine should be given once in a lifetime.

View More Reports Related To The Therapeutic BCG Vaccines Market –
Therapeutic Proteins Global Market Report 2023
Veterinary Vaccines Global Market Report 2023
Swine Vaccines Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: